HAE

SEC source: 0001127602-24-016816 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,825

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016813 · form4.xml · nonDerivative · entry 2

Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,940

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016813 · form4.xml · nonDerivative · entry 1

Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,450

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016810 · form4.xml · nonDerivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,247

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016810 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,005

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016807 · form4.xml · nonDerivative · entry 2

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,045

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016807 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,823

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016803 · form4.xml · nonDerivative · entry 2

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 329,361

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016803 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,097

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016801 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,053

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016801 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,452

F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016175 · form4.xml · derivative · entry 7

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,242

Underlying: Common Stock · 2,241 shares

Expires 2028-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F8 · derivative.exercise_date: Reflects options granted on May 18, 2021 that vest in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 5

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,196

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 4

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,882

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F6 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 3

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,437

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016169 · form4.xml · nonDerivative · entry 4

Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,310

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated August 28, 2023 (fully executed as of August 31, 2023).

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016164 · form4.xml · nonDerivative · entry 4

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,257

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016177 · form4.xml · derivative · entry 2

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,291

Underlying: Common Stock · 1,291 shares

Expires 2031-05-17

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016177 · form4.xml · nonDerivative · entry 1

Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,144

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016175 · form4.xml · derivative · entry 6

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,313

Underlying: Common Stock · 6,313 shares

Expires 2031-05-17

F7 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,196

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 1

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,324

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016173 · form4.xml · derivative · entry 3

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,591

Underlying: Common Stock · 4,591 shares

Expires 2031-05-17

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016173 · form4.xml · nonDerivative · entry 2

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,173

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016173 · form4.xml · nonDerivative · entry 1

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,084

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016171 · form4.xml · derivative · entry 3

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,461

Underlying: Common Stock · 7,461 shares

Expires 2031-05-17

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016171 · form4.xml · nonDerivative · entry 2

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,685

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016171 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,291

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016169 · form4.xml · nonDerivative · entry 3

Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,297

F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F5 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016169 · form4.xml · nonDerivative · entry 2

Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,030

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016169 · form4.xml · nonDerivative · entry 1

Llorens Josep · CIK 0001750812 · EVP, Global Manufacturing

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,350

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated August 28, 2023 (fully executed as of August 31, 2023).

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016166 · form4.xml · derivative · entry 2

Galvin Roy · CIK 0001950021 · President, Global Plasma & BC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,313

Underlying: Common Stock · 6,313 shares

Expires 2031-05-17

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016166 · form4.xml · nonDerivative · entry 1

Galvin Roy · CIK 0001950021 · President, Global Plasma & BC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,410

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016164 · form4.xml · derivative · entry 5

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,183

Underlying: Common Stock · 9,183 shares

Expires 2031-05-17

F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016164 · form4.xml · nonDerivative · entry 3

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,861

F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F5 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016164 · form4.xml · nonDerivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,683

F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016164 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,352

F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).

F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported.

SEC source: 0001127602-24-016162 · form4.xml · derivative · entry 2

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,756

Underlying: Common Stock · 9,756 shares

Expires 2031-05-17

F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016162 · form4.xml · nonDerivative · entry 1

DArecca James · CIK 0001583903 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,346

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016160 · form4.xml · derivative · entry 3

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,140

Underlying: Common Stock · 32,140 shares

Expires 2031-05-17

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-016160 · form4.xml · nonDerivative · entry 2

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,035

F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.

F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-016160 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,411

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-015888 · form4.xml · derivative · entry 6

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,821

Underlying: Common Stock · 2,410 shares

Expires 2029-05-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 5

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,608

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 4

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,341

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F4 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 3

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,018

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 2

Strong Stewart W · CIK 0001420910 · President, Global Hospital

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,608

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-24-015872 · form4.xml · nonDerivative · entry 3

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,425

F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-015872 · form4.xml · nonDerivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,410

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-24-015870 · form4.xml · nonDerivative · entry 2

Miller Laurie A. · CIK 0001881751 · SVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,160

F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

F2 · balance_after: This number includes unvested RSUs previously reported, 134 shares acquired by the reporting person on October 31, 2023 under the Issuer's 2007 Employee Stock Purchase Plan (as amended, the "ESPP") and 129 shares acquired by the reporting person on April 30, 2024 under the ESPP.